Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy

Author:

Pitter Kenneth L1ORCID,Casey Dana L1,Lu Yue C1,Hannum Margaret2ORCID,Zhang Zhigang2,Song Xinmao1,Pecorari Isabella1,McMillan Biko1ORCID,Ma Jennifer1,Samstein Robert M1,Pei Isaac X1,Khan Atif J1,Braunstein Lior Z1ORCID,Morris Luc G T3ORCID,Barker Christopher A1,Rimner Andreas1ORCID,Alektiar Kaled M1,Romesser Paul B1,Crane Christopher H1,Yahalom Joachim1ORCID,Zelefsky Michael J1,Scher Howard I4,Bernstein Jonine L2,Mandelker Diana L5,Weigelt Britta5,Reis-Filho Jorge S56ORCID,Lee Nancy Y1,Powell Simon N17,Chan Timothy A168,Riaz Nadeem18,Setton Jeremy1ORCID

Affiliation:

1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

6. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

7. Molecular Biology Program, Sloan Kettering Institute, New York, NY, USA

8. Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract

Abstract Background Radiation therapy is one of the most commonly used cancer therapeutics but genetic determinants of clinical benefit are poorly characterized. Pathogenic germline variants in ATM are known to cause ataxia-telangiectasia, a rare hereditary syndrome notable for marked radiosensitivity. In contrast, somatic inactivation of ATM is a common event in a wide variety of cancers, but its clinical actionability remains obscure. Methods We analyzed 20 107 consecutively treated advanced cancer patients who underwent targeted genomic sequencing as part of an institutional genomic profiling initiative and identified 1085 harboring a somatic or germline ATM mutation, including 357 who received radiotherapy (RT). Outcomes of irradiated tumors harboring ATM loss-of-function (LoF) mutations were compared with those harboring variants of unknown significance. All statistical tests were 2-sided. Results Among 357 pan-cancer patients who received 727 courses of RT, genetic inactivation of ATM was associated with improved radiotherapeutic efficacy. The 2-year cumulative incidence of irradiated tumor progression was 13.2% vs 27.5% for tumors harboring an ATM LoF vs variant of unknown significance allele, respectively (hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.34 to 0.77, P = .001). The greatest clinical benefit was seen in tumors harboring biallelic ATM inactivation (HR = 0.19, 95% CI = 0.06 to 0.60, P = .005), with statistically significant benefit also observed in tumors with monoallelic ATM inactivation (HR = 0.57, 95% CI = 0.35 to 0.92, P = .02). Notably, ATM LoF was highly predictive of outcome in TP53 wild-type tumors but not among TP53-mutant tumors. Conclusions We demonstrate that somatic ATM inactivation is associated with markedly improved tumor control following RT. The identification of a radio-sensitive tumor phenotype across multiple cancer types offers potential clinical opportunities for genomically guided RT.

Funder

National Institutes of Health K12

National Cancer Institute at the National Institutes of Health Cancer Center

PaineWebber Chair

Breast Cancer Research Foundation

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3